For the quarter ending 2026-03-31, TNXP made $6,878K in revenue. -$40,194K in net income. Net profit margin of -584.38%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2024-09-30 |
|---|---|---|---|---|
| Product revenue, net | 6,878 | 3,237* | 3,290 | 2,822 |
| Cost of sales | 1,578 | 2,539* | 1,367 | 1,555 |
| Research and development | 18,213 | 16,686* | 9,289 | 9,114 |
| Selling general and administrative | 28,624 | 10,581* | 25,701 | 7,707 |
| Total operating expenses | 48,415 | 29,806* | 36,357 | 18,376 |
| Operating loss | -41,537 | -26,569* | -33,067 | -15,554 |
| Grant income | 0 | 66* | 982 | 1,668 |
| Loss on extinguishment of debt | 0 | -2,092* | 0 | - |
| Interest income | 1,346 | 453* | 1,231 | - |
| Interest expense | - | 22* | - | - |
| Other expense, net | -3 | 173* | -1,156 | -327 |
| Net loss available to common stockholders | -40,194 | -27,991 | -32,010 | -14,213 |
| Basic EPS | -2.93 | -3.456 | -3.59 | -0.23 |
| Diluted EPS | -2.93 | -3.456 | -3.59 | -0.23 |
| Basic Average Shares | 13,707,104 | 8,099,844 | 8,922,792 | 62,122,283 |
| Diluted Average Shares | 13,707,104 | 8,099,844 | 8,922,792 | 62,122,283 |
Tonix Pharmaceuticals Holding Corp. (TNXP)
Tonix Pharmaceuticals Holding Corp. (TNXP)